19:50 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Seattle Genetics gets $30M milestone for EU approval of Adcetris in first-line Hodgkin lymphoma

Seattle Genetics Inc. (NASDAQ:SGEN) will receive a $30 million milestone payment from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) triggered by the European Commission's decision to expand the label of Adcetris brentuximab vedotin to include previously untreated...
13:51 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute promyelocytic leukemia (APL); breast cancer Cell culture and mouse studies suggest liposomal co-delivery of the antioxidant quercetin and doxorubicin could help treat doxorubicin-resistant APL, breast cancer and other cancers. In doxorubicin-resistant human APL...
00:40 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said on Jan. 18 that it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE trial to treat advanced or metastatic soft...
13:43 , Jan 18, 2019 |  BC Extra  |  Clinical News

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE study to treat advanced or metastatic soft tissue sarcoma. The trial...
05:04 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

Lynparza meets in postapproval Phase III for relapsed ovarian cancer, gets first-line maintenance approval

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said on Dec. 20 that Lynparza olaparib met the primary endpoint of improving objective response rate (ORR) vs. physician’s choice of single-agent chemotherapy in...
01:09 , Jan 4, 2019 |  BC Week In Review  |  Company News

Lee's subsidiary gets Chinese rights to Auransa's cardioprotective agent

China Oncology Focus Ltd. received exclusive Chinese rights to preclinical candidate AU018 from AI company Auransa Inc. (Palo Alto, Calif.). China Oncology Focus also gained rights to AU018 in other undisclosed countries in Southeast Asia....
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
23:22 , Dec 14, 2018 |  BC Extra  |  Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The agency...
21:06 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting P4HA1 could help treat triple-negative breast cancer (TNBC). In tumor samples from TNBC patients, levels of P4HA1 protein were higher than in samples from estrogen...